sarepta.com (SRPT): Market Cap to Earnings and Growth Ratio

Brandmark of sarepta.com (SRPT)

Sarepta Therapeutics, Inc. (SRPT) generates revenue based on the exclusive distribution of RNA-based drugs, while external risks remain minimal due to stable supply chains. The current PEG ratio demonstrates the asset's value dynamics, where the 2.07 mark characterizes this parameter. The company's growth trajectory relies on its dominance in the precision therapy segment for rare genetic pathologies.

SRPT - Sarepta PEG Multiple over the range 07/04/2022 - 11/17/2026

Sarepta Therapeutics, Inc. (SRPT) - metric breakdowns and financial figures

- current quotes and average value forecast:
General company analysis:Sarepta Therapeutics Inc, SRPT
Finished products of Sarepta Corp

Finding a balance between operational risks and return on capital requires an analysis of the ratio of the market value of earnings to their growth rate. Due to a patent monopoly and inelastic demand for RNA drugs, the historical PEG level for Sarepta Therapeutics, Inc. (SRPT) reflects the efficiency of capitalizing on unique advantages; a value below one signals that the business is undervalued relative to its expansion.

Competing companies

PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|CRSP (CRISPR Therapeutics Corp) - Price/Earnings to Growth Multiple|GeneDx Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ultragenyx|Price to Earnings Adjusted for Growth Rate beamtx.com BEAM|Price/Earnings to Growth Ratio Twist Bioscience Corp (TWST)|Price/Earnings to Growth Multiple 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio STOK|BLFS - Price/Earnings to Growth Ratio|Wave Life Sciences (WVE) - Price/Earnings to Growth Multiple|MAZE: PEG Multiple|Sionna Therapeutics, Inc. (SION) - PEG Multiple|Price/Earnings to Growth Ratio Prime Medicine, Inc.|TSHA (Taysha) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple QURE (uniQure Pharma)|Growth-Adjusted Market Cap to Net Income meiragtx.com|Price/Earnings to Growth Ratio REGENXBIO RGNX|SLDB - Price/Earnings to Growth Multiple|Ocugen, Inc. - PEG Multiple|PACB (Pacific Biosciences of California) - Growth-Adjusted P/E Ratio|BNTC: PEG Multiple|DSGN - Growth-Adjusted Market Cap to Net Income|RCKT (Rocket Pharma) - PEG Multiple|Price/Earnings to Growth Ratio FDMT|Price/Earnings to Growth Ratio Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Growth-Adjusted P/E Ratio|editasmedicine.com - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income silence-therapeutics.com (SLN)|PRQR: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate codexis.com|SGMO: PEG Multiple|Price to Earnings Adjusted for Growth Rate Nautilus Biotechnology Inc (NAUT)|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Corp (GBIO)|Boundless Bio - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure, Inc. XCUR|Growth-Adjusted Payback Ratio IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio Inc MBIO|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bluebird Bio BLUE|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income